Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies
,
Abstract
Introduction: Allogeneic hematopoietic stem cell transplantation is a potentially curative treatment modality for hematological malignancies. We evaluated the outcome of patients suffering from hematological malignancies, including acute leukemias, chronic myeloid leukemia and myelodysplastic syndrome after allogeneic transplantation.
Methods: All patients having hematological malignancies with HLA identical sibling donors who underwent allogeneic transplantation were included. Pre-transplant workup consisted of complete blood counts, evaluation of liver, kidneys, lungs, infectious profile, chest X-ray, paranasal sinus roentgenograms and dental review. Donors were given G-CSF at a dose of 5-10 μg/kg/twice daily for five days prior to harvest. The conditioning regimens included cyclophosphamide, busulfan and total body irradiation.
Results: A total of 41 allogeneic transplants were performed for hematological malignancies from April 2004 to December 2012. There were 31 males and 10 females. Median age ± SD was 28 ± 11.7 years (range 8 - 54 years). A mean of 7.7×108±1.5 mononuclear cells/kg were infused (range:6.2-9.2×108/kg). The median time to white cell recovery was 19±4 days (range:15-23 days). Transplant related mortality was 19.5%. The median overall survival was 53.6 months. Overall survival at a median follow up of 37 months was 67%.
Conclusion: Allogeneic stem cell transplantation is an effective treatment option in patients with hematological malignancies. Our outcomes are comparable with results from neighboring countries as well as the western world.
Ali N, Adil SN, Shaikh MU, Masood N. Frequency and Outcome of Graft versus Host Disease after Stem Cell Transplantation: A Six-Year Experience from a Tertiary Care Center in Pakistan. ISRN hematology.2013.http://www.ncbi.nlm.nih.gov/pubmed/23936661
Huynh TN, Weigt SS, Belperio JA, Territo M, Keane MP. Outcome and prognostic indicators of patients with hematopoietic stem cell transplants admitted to the intensive care unit. Journal of transplantation. 2009;2009.http://www.ncbi.nlm.nih.gov/pubmed/20130763
Copelan EA. Hematopoietic stem-cell transplantation. New England Journal of Medicine. 2006;354(17):1813-26.http://www.ncbi.nlm.nih.gov/pubmed/16641398
Sullivan KM, Storb R. Allogeneic marrow transplantation. Cancer investigation. 1984;2(1):27-38.http://www.ncbi.nlm.nih.gov/pubmed/6367899
Hashmi K, Khan B, Ahmed P, Hussain I, Raza S, Iqbal H, et al. Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukaemia- A 2 ½ Year Experience. Journal of the Pakistan Medical Association. 2005;55(11):478-82.http://www.ncbi.nlm.nih.gov/pubmed/16304866
Shamsi TS, Irfan M, Ansari SH, Farzana T, Khalid MZ, Panjwani VK, et al. Allogeneic peripheral blood stem cell transplantation in patients with haematological malignancies. Journal of the College of Physicians and Surgeons--Pakistan: JCPSP. 2004;14(9):522-6.http://www.ncbi.nlm.nih.gov/pubmed/15353134
Ullah K, Ahmed P, Raza S, Satti T, Nisa Q, Mirza S, et al., editors. Allogeneic stem cell transplantation in hematological disorders: single center experience from Pakistan. Transplantation proceedings; 2007. Elsevier.http://www.ncbi.nlm.nih.gov/pubmed/18089384
Shamsi TS, Hashmi K, Adil S, Ahmad P, Irfan M, Raza S, et al. The stem cell transplant program in Pakistan - the first decade. Bone marrow transplantation. 2008;42:S114-S7.http://www.ncbi.nlm.nih.gov/pubmed/18724282
Chen Y, Xu Y, Zhu Y, Fu G, Liu Y, Peng J, et al. [Clinical analysis of 104 patients with hematological malignancy after allogeneic hemotopoietic stem cell transplantation]. Zhong nan da xue xue bao Yi xue ban= Journal of Central South University Medical sciences.36(9):859-64.http://www.ncbi.nlm.nih.gov/pubmed/21946205
Iravani M, Evazi MR, Mousavi SA, Shamshiri AR, Tavakoli M, Ashouri A, et al. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high-and standard-risk leukemic patients. Bone marrow transplantation. 2007;40(2):105-10.http://www.ncbi.nlm.nih.gov/pubmed/17468775
Chandy M, Srivastava A, Dennison D, Mathews V, George B. Allogeneic bone marrow transplantation in the developing world: experience from a center in India. Bone marrow transplantation. 2001;27(8):785-90.http://www.ncbi.nlm.nih.gov/pubmed/11477434
Schmitz N, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E, et al. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. haematologica. 2005;90(5):643-8.http://www.haematologica-thj.org/content/90/5/643.full.pdf
Gratwohl A. The EBMT risk score. Bone marrow transplantation.47(6):749-56.http://www.ncbi.nlm.nih.gov/pubmed/21643021
Bishop JF. The treatment of adult acute myeloid leukemia. Semin Oncol 1997 Feb;24(1):57-69.http://www.ncbi.nlm.nih.gov/pubmed/9045305
Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood. 1995;85(6):1655-8.http://www.ncbi.nlm.nih.gov/pubmed/7534140
Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. New England Journal of Medicine. 2001;344(3):175-81.http://www.ncbi.nlm.nih.gov/pubmed/11172139
Schmitz N, Bacigalupo A, Hasenclever D, Nagler A, Gluckman E, Clark P, et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone marrow transplantation. 1998;21(10).http://www.ncbi.nlm.nih.gov/pubmed/9632272
Bone Marrow Transplant Clinic - The Aga Khan University Hospital. Available at: http://hospitals.aku.edu/karachi/hospitaldepartments/medicine/Pages/specialservicesbonemarrow.aspx
Wu HX, Qian SX, Hong M, Zhang YP, Lu H, Zhang R, et al. [Allogeneic peripheral blood stem cell transplantation for 75 cases of hematologic malignancies]. Zhongguo shi yan xue ye xue za zhi/Zhongguo bing li sheng li xue hui= Journal of experimental hematology/Chinese Association of Pathophysiology. 2008;16(6):1330-3.http://www.ncbi.nlm.nih.gov/pubmed/19099638
Couban S, Simpson DR, Barnett MJ, Bredeson C, Hubesch L, Howson-Jan K, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood. 2002;100(5):1525-31.http://www.ncbi.nlm.nih.gov/pubmed/12176866
Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P, et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone marrow transplantation. 2005;36(9):757-69.http://www.ncbi.nlm.nih.gov/pubmed/16151426
Vigorito AC, Azevedo WM, Marques JFC, Azevedo AM, Eid KAB, Aranha FJP, et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone marrow transplantation. 1998;22(12).http://www.ncbi.nlm.nih.gov/pubmed/9894716
Nagafuji K, Matsuo K, Teshima T, Mori S-i, Sakamaki H, Hidaka M, et al. Peripheral blood stem cell versus bone marrow transplantation from HLA-identical sibling donors in patients with leukemia: a propensity score-based comparison from the Japan Society for Hematopoietic Stem Cell Transplantation registry. International journal of hematology.91(5):855-64.http://www.ncbi.nlm.nih.gov/pubmed/20464644
Ringden O, Labopin M, Bacigalupo A, Arcese W, Schaefer UW, Willemze R, et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002 Dec 15;20(24):4655-64.http://www.ncbi.nlm.nih.gov/pubmed/12488410
Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood. 2000;95(12):3702-9.http://www.ncbi.nlm.nih.gov/pubmed/10845900
Disease-specific HCT indications and outcome - CIBMTR. Available at: https://bethematchclinical.org/Transplant-Indications-and-Outcomes/Disease-Specific-Indications-and-Outcomes/
Oehler VG, Radich JP, Storer B, Blume KG, Chauncey T, Clift R, et al. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biology of Blood and Marrow Transplantation. 2005;11(2):85-92.http://www.ncbi.nlm.nih.gov/pubmed/15682068
Elmaagacli AH, Basoglu S, Peceny R, Trenschel R, Ottinger H, Lollert A, et al. Improved disease-free survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood. 2002;99(4):1130-5.http://www.ncbi.nlm.nih.gov/pubmed/11830457
Imamura M, Asano S, Harada M, Ikeda Y, Kato K, Kato S, et al. Current status of hematopoietic cell transplantation for adult patients with hematologic diseases and solid tumors in Japan. Int J Hematol 2006 Feb;83(2):164-78.http://www.ncbi.nlm.nih.gov/pubmed/16513537
| Files | ||
| Issue | Vol 8, No 4 (2014) | |
| Section | Articles | |
| Keywords | ||
| Allogeneic transplantation Hematological malignancies Hematopoietic stem cell transplantation Treatment Outcome | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
